Skip to content

Study Comparing Intensive Radiotherapy Versus Conventional ChemoRadiotherapy In Cervical Cancer

A Prospective Randomized Study Comparing Accelarated Radiotherapy Versus Conventional Concomitant ChemoRadiation In Locally Advanced Carcinoma Cervix

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013215
Enrollment
92
Registered
2018-04-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Locally Advanced Cervical Cancer.

Interventions

Intervention1: True accelerated radiation alone with reduced overall treatment duration to Conventional Concomitant Chemoradiation in Locally Advanced Carcinoma Cervix: The s

Sponsors

Dr Debashis Das
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 35 -60yrs 2. No history of Pelvicoperation 3. Pathologically proved carcinoma cervix (FIGO stage 2B to 4A)4.Patient signed consent forms.5. No prior history of malignancy. 6.Karnofsky Performance Status (KPS) >= 70. 7. No prior history of exposure tocytotoxic chemotherapy or radiation. 8. No clinical or radiological evidenceof metastasis at presentation. 9. Adequate bone marrow function: Hb > 10g/dl; WBC > 4000/mm3 (ANC >= 2000/mm3); Platelets >= 1,00,000/mm3.

Exclusion criteria

Exclusion criteria: 1. Age >=60 2. Pregnancy 3. History of Pelvicoperation 4. Stage 4B disease . 5. Karnofsky Performance Status (KPS) <70. 6. Participation in any other study on cancer cervix. 7. Prior pelvic radiation.

Design outcomes

Primary

MeasureTime frame
To assess and compare the response and safety of true accelerated radiation alone with reduced overall treatment duration to conventional concomitant chemoradiation in locally advanced carcinoma cervix .Timepoint: One Year and Six Months

Secondary

MeasureTime frame
a. Assessment of response b. Detection of recurrence, if any c. Assessment of quality of life d. Assessment of toxicity(acute & late).Timepoint: One Year and Six Months

Countries

India

Contacts

Public ContactDr Debashis Das

Calcutta Medical College, Kolkata

asitrdeb@rediffmail.com9830583960

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026